Edward Lifesciences rises as demand for heart device drives Q4 profit beat

Edwards Lifesciences

12/02/2025 14:30

** Medical device maker Edward Lifesciences' shares  EW.N 
rise 4.4% to $74 premarket 
    ** Co on Tuesday reported Q4 profit of 59 cents/share,
beating analyst est of 55 cents/share - LSEG data 
    ** Co posted Q4 total sales of $1.39 billion, higher than
analyst est of $1.35 bln 
    ** EW's lead product, transcatheter aortic valve replacement
(TAVR) device, brought in Q4 sales of $1.04 billion vs analyst
est of $1.01 billion 
    ** At least three brokerages raised PT on the stock
following results 
    ** Brokerage William Blair says EW is well positioned to
meet its financial goals this year 
    ** Co's performance could be boosted by potential insurance
coverage for its tricuspid valve replacement devices, broader
approval of TAVR procedures and regulatory approval of the
Sapien M3 heart valve in the U.S and the EU, the brokerage said
    ** Stock fell 16.5% in the last 12 months 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com;))